AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. The new results come from the EMERALD-3 study, testing a ...
Trump started the Section 232 probe into pharma in the spring of 2025, using it as a lever for trade negotiations and MFN ...
Sebnem Avsar Tuna, general manager of Novo Nordisk UK, reflected on how advances in biology and research have helped reshape ...
For Korsana, merging with Cyclerion gives it a fast track to a Nasdaq listing without the complexities of going down the IPO ...
For Lebrat, it goes back to simplicity of use: the synthetic persona leverages the data a team already has. Synthetic ...
The FDA has approved orforglipron, under the Foundayo trade name, in just 50 days, thanks to a fast track review under the ...
The 2026 agenda is anchored by a distinguished roster of speakers who are actively redefining the boundaries of science, ...
In a subgroup of black women enrolled in a US breast cancer registry called BEST, women deemed to have low-risk tumours using the MammaPrint test had a 97.7% recurrence-free rate after 10 years, the ...
At the LSX World Congress in Lisbon this year, web editor Nicole Raleigh stepped aside from the hustle and bustle to speak ...
"Through the integration of virtual control groups, EMA also seeks to improve the relevance and predictability of ...
Three behavioural phenomena are particularly consequential in screening and prevention research: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results